[ad_1]
dusseldorf, Germany, August 4, 2022 /PRNewswire/ — LenioBio GmbH, the German life science biotech provider of controversial protein production technology, today announced the appointment of Mr. Jasper Levinck to the management team in charge of core business operations.
In his new role as Chief Business Officer, Mr. Levinck will be responsible for driving LenioBion’s business development and business strategy.
“We are delighted that Jasper Levinck has agreed to take on this senior role at LenioBio,” said CEO. Remberto Martis. “The company will benefit from Mr. Levinck’s extensive expertise in business and strategy development in biotech. Jasper Levinck’s appointment comes at a time when we have grown our platform and now need to expand our business development efforts.”
Mr. Levinck joined Leniobayo January 2022 As the Alternative Proteins business unit leader, it is focused on introducing the LenioBio expression platform in alternative protein applications such as processed meats and cosmetics. He will continue in this role in parallel with his new appointment.
“I am inspired by the potential of LenioBio’s ALiCE® technology. I am particularly excited about the ways in which ALiCE® can disrupt drug discovery, development and production.” “I look forward to working with the rest of the leadership team to develop our business to achieve these goals,” said Mr. Levinck.
Mr. Levinck brings to LenioBio more than 11 years of business development and strategic consulting experience in the life sciences and healthcare sectors. Until recently, he held senior roles at ttopstart BV, funding scientists and companies and building smart strategies, raising over 500 million euros in funding. Mr Levinck is the founder of a care facility for young people with mental health problems and co-founder of Doctors, a Dutch organization improving GP care.
This new appointment follows the announcement that the company has achieved a significant milestone in the commercialization of its cell-free protein synthesis platform, ALiCE®.
Full details of the LenioBio Leadership Team are available online at www.leniobio.com/team.
About LenioBio
LenioBio is a protein expression platform company committed to advancing transformative technology for the discovery, development and large-scale production of proteins not limited by cell limitations.
LenioBio was established as a legal entity in Germany in September 2016with offices Dusseldorf and R&D and production laboratories in Aachen. For more information, visit Leniobio.com and follow LenioBio on LinkedIn.
Logo – https://mma.prnewswire.com/media/1758134/LenioBio_Logo.jpg
Source LenioBio GmbH
[ad_2]
Source link
